Ibnsina Pharma results, Q3 2024
Net profit, assets, equity and cash flow for Q3 2024, against the same period a year earlier, from the published financial statements.
Net profit185 millionEGP · +339.9% vs the same period a year earlier
Total assets26.16 billionEGP · +40.0% vs the same period a year earlier
Shareholders' equity1.82 billionEGP · +29.3% vs the same period a year earlier
Operating cash flow353 millionEGP · +214.0% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q3 2024 was about 185 million EGP, up +339.9% from 42.03 million EGP in Q3 2023.
- Total assets at the end of Q3 2024 were about 26.16 billion EGP, and shareholders' equity about 1.82 billion EGP.
- Operating cash flow for Q3 2024 was positive at 353 million EGP.
Key lines against the same period a year earlier
This periodQ3 2023Change
Net profit185 million42.03 million+339.9%
Gross profit1.23 billion701 million+75.2%
Total assets26.16 billion18.68 billion+40.0%
Total liabilities24.34 billion17.27 billion+40.9%
Shareholders' equity1.82 billion1.41 billion+29.3%
Total liabilities and equity26.16 billion18.68 billion+40.0%
Operating cash flow353 million-310 million+214.0%
Investing cash flow-45.34 million-135 million+66.3%
Financing cash flow-603 million480 million−225.6%
Net change in cash-295 million35.88 million−922.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy